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We evaluated the effect of the pregnane X receptor agonist, pregnenolone 16 alpha-carbonitrile 
(PCN) on the expression levels of plasma monoamine transporter (PMAT) in the intestine. Male 
C57/BL6 mice were divided into two 2 groups: mice in the PCN group (n=3) were administered 
PCN once a day for 4 days, while those in the control group (n=3) received the same volume of 
vehicle once a day for 4 days. After the mice were killed 24 h after administration of the last dose of 
PCN or vehicle, and the expression levels of PMAT in the intestine tissues were isolated and mea-
sured the expression level of PMAT using immunohistochemical and western blotting analyses. The 
expression level of PMAT expression levels in the small intestine increased after PCN treatment. 
These results suggest that the induction of PMAT may play a clinically significant role by increasing 
intestinal absorption of PMAT substrates such as metformin.
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Introduction
  Organic cation drugs are distributed in the body via a spe-
cific transport system consisting of organic cation transporters 
(OCTs) of the solute carrier 22 (SLC22) family and multidrug 
and toxin extrusion proteins (MATEs) from the SLC47 family.
[1,2] Recently, Engel et al. reported a new polyspecific organic 
cation transporter known as the plasma membrane monoamine 
transporter (PMAT, SLC29A4), which is an Na+-independent 
and membrane potential-sensitive transporter that transports 
monoamine neurotransmitters and neurotoxin 1-methyl-
4-phenylpyridinium (MPP+).[3] Functionally, PMAT shares 
its substrate and the specificity of its inhibitors with OCTs.[3-
5] Metformin, an organic cation drug, is also transported by 
PMAT.[6] PMAT is expressed in the small intestine, kidney, 
heart, and brain.[6,7] Zhou et al. reported localization of PMAT 
in the mucosal epithelial layer of the human small intestine.
[6] Considering that the Km value of metformin for PMAT, 
hOCT1, and hOCT2 is 1320, 1470, and 1380 µM, respective-
ly,[6] metformin transportation by PMAT is comparable to that 
by OCTs. Since the expression level of PMAT in the small intes-
tine is considerable, PMAT may play an important role in met-
formin absorption in the small intestine. Interestingly, our pre-
vious study has indicated that the absorption of metformin was 
increased in healthy volunteers after administration of rifampin, 
a pregnane X receptor (PXR) agonist.[8] Similarly, the PXR 
agonist pregnenolone 16 alpha-carbonitrile (PCN) has demon-
strated potential effects of inducing some drug transporters in 
animal models. PCN increased the mRNA levels of OCTs, but 
not of the multidrug and toxic extrusion (MATE) transporter.
[9,10] Therefore, we hypothesized that PCN increases PMAT’s 
expression levels in the small intestine and may contribute to 
increased absorption of metformin. We determined the protein 
levels of PMAT in the presence and absence of PCN treatment 
in mice and compared PMAT expression levels.
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PCN Increases PMAT Expression
Materials and Methods 
Animals
  Six-week-old male C57/BL6 mice were used in this study. Ex-
periments were performed in accordance with the guidelines 
and regulations of Yonsei University Medical College and ap-
proved by the Association for Assessment and Accreditation 
of Laboratory Animal Care (AAALAC). Animals in the PCN 
group (n=3) were intraperitoneally (i.p.) administered a single 
dose of 75 mg/kg body weight (15 mg/ml in propylene glycol) 
once a day for 4 days. In contrast, animals in the control group 
(n=3) were injected with the same volume of vehicle once a day 
for 4 days. The mice were then sacrificed 24 h after administra-
tion of the last dose of PCN or vehicle.
Immunohistochemical analysis
  To examine the tissue for morphological changes, we per-
formed immunohistochemical staining on 4% formalin-fixed, 
paraffin-embedded tissue samples. Tissues sections attached to 
a saline-coated slide were incubated overnight at 37°C, deparaf-
finized in xylene (3×10 min), and rehydrated through a graded 
alcohol series (100%, 95%, 90%, 80%, 70%) diluted in water. The 
paraffinized sections were heated and then boiled (3×10 min) 
by microwaving in 0.01 M citrate buffer (pH 6.0) for antigen 
retrieval. Antibodies against PMAT protein (ab75615; 1:50; Ab-
cam, UK) were applied and incubated at 4°C overnight. After 
3 PBS washes, the sections were incubated in biotinylated link 
(LSAB2; Dako A/S, Glostrup, Denmark) for 20 min, and then 
washed with PBS 3 times. The peroxidase-binding site was de-
tected by a diaminobenzidine reaction (DAB; DAKO A/S).
Western blot analysis
  Western blotting was performed according to previously de-
scribed methods using antibodies against PMAT (ab75615; 
1:100; Abcam, UK).[11,12] Antibodies were used at the dilution 
recommended by the manufacturer. The samples in each group 
were pooled.
Results
Histological and western blotting 
  Histological findings in the PCN group revealed a difference 
between the control group and PCN group of C57/BL6 mice. 
Figure 1 is a representative immunohistochemistry image for 
PMAT staining in the small intestine. The most obvious PCN-
induced changes in the immunohistochemical findings were the 
increased expression levels of PMAT. The PCN administration 
group showed greater PMAT staining density than the control 
group located in the apical and basolateral membrane of epi-
thelial cells in the small intestine. As shown in the western blot 
analysis in Figure 2, the protein expression levels of PMAT in 
the small intestine and liver also increased in PCN-treated mice.
Discussion
  Consistent with the results of a previous report,[6] PMAT 
was expressed in the small intestine of the mice in our study. 
Our results demonstrated that PCN treatment increased the 
expression levels of PMAT in the small intestine. These result 
are in line with our previous clinical study that the PXR agonist 
rifampin enhanced the absorption of metformin in healthy 
volunteers.[8] PMAT is a known transporter of metformin in 
the small intestine.[6] Thus, the enhanced absorptive activity of 
metformin may be mediated by the PCN-induced increase in 
PMAT expression. The effect of the transactivator PXR has been 
well described in several studies on metformin transport. PXR 
has not been shown to affect the expression level of MATEs, but 
has demonstrated effects on OCTs.[9,10] However, the effect of 
PXR on PMAT expression has been unknown. To the best of 
our knowledge, this is the first study to report that a PXR ago-
nist increases the expression levels of PMAT in the small intes-
tine. 
  OCT1 and OCT3 are also localized in the intestine[13] but the 
expression level was much lower than liver. Although the rela-
tive intestinal or hepatic expression level of PMAT compared 
Figure 1. Effect of pregnenolone 16 alpha-carbonitrile (PCN) on PMAT 
expression in C57/BL6 mice. Representative immunohistochemical 
images for PMAT staining in the small intestine in the control (left) and 
PCN (right) animals.
Figure 2. The effect of PCN on PMAT expression in the liver and small 
intestine as assessed using western blotting analyses (samples were 
pooled).
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to OCT1 or OCT3 has been unknown in human, increased 
levels of PMAT may have contributed to the enhanced uptake 
of PMAT substrate such as metformin and possibly its effect. 
PMAT in other organs including liver and brain would be 
induced by PCN treatment. We also obtained liver samples 
and observed an increased expression in western blot analysis 
but immunohistochemistry finding was not definite (data not 
shown). Monoamine neurotransmitters (e.g. dopamine, sero-
tonin) are known PMAT substrates and induced brain PMAT 
would. affect these neurotransmitters’ activities. 
  There are some limitations in this study. First, no quantita-
tive PMAT mRNA analysis was performed. PCN treatment 
is expected to increase PMAT mRNA by transcriptional up-
regulation. However, it is rational to infer that the increased 
PMAT protein expression was mediated by increased tran-
scription because PCN is a specific PXR agonist activating 
transcription. Second, other transactivators may contribute 
to the increased levels of PMAT. For example, the peroxisome 
proliferator agonist receptor-alpha and receptor-gamma have 
been shown to affect the transcriptional regulation of OCT1.
[14] Moreover, despite the lack of available data on its effects, 
constitutive androstane receptor (CAR) might contribute to the 
transcription of this transporter.[15] In addition, the pharma-
cokinetics of PMAT substrates such as metformin before and 
after PCN treatment may contribute to the interpretation of our 
results. Third, the small number of samples and no statistical 
analysis may be not sufficient to warrant our conclusion, but the 
increased staining results in immunohistochemistry were con-
sistent in all of the samples from different tissues. Finally, our 
results cannot be readily extrapolated to humans; it is necessary 
to measure the changes in PMAT expression levels in the hu-
man small intestine before and after rifampin treatment, which 
will require a more invasive endoscopic biopsy.
  In summary, we found that the PXR agonist PCN increased 
the expression levels of PMAT in the small intestine. The results 
of this study imply that induction of PMAT may contribute to 
increased transport activity of PMAT substrates in the small 
intestine and probably enhance its absorption. 
Acknowledgments
  This study was supported by the Basic Science Research Pro-
gram through the National Research Foundation of Korea 
(NRF), which is funded by the Ministry of Education, Science 
and Technology (2011-0009540). In addition, the Health Fel-
lowship Foundation supported this study.
Conflict of Interest
  None of the authors has any conflicts of interest regarding this 
study.
References
 1.  Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. Substrate 
specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/
H(+)-organic cation antiporters. Biochem Pharmacol 2007;74:359-371.
 2.  Sugawara-Yokoo M, Urakami Y, Koyama H, Fujikura K, Masuda S, Saito 
H, et al. Differential localization of organic cation transporters rOCT1 and 
rOCT2 in the basolateral membrane of rat kidney proximal tubules. Histo-
chem Cell Biol 2000;114:175-180.
 3.  Engel K, Zhou M, Wang J. Identification and characterization of a novel 
monoamine transporter in the human brain. J Biol Chem 2004; 279:50042-
5049.
 4.  Ho HT, Pan Y, Cui Z, Duan H, Swaan PW, Wang J. Molecular analysis and 
structure-activity relationship modeling of the substrate/inhibitor interaction 
site of plasma membrane monoamine transporter. J Pharmacol Exp Ther 
2011;339:376-385.
 5.  Engel K, Wang J. Interaction of organic cations with a newly identified 
plasma membrane monoamine transporter. Mol Pharmacol 2005;68:1397-
1407.
 6.  Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-
stimulated organic cation transporter (plasma membrane monoamine 
transporter) expressed in human intestine. Drug Metab Dispos 2007;35: 
1956-1962.
 7.  Xia L, Zhou M, Kalhorn TF, Ho HT, Wang J. Podocyte-specific expression 
of organic cation transporter PMAT: implication in puromycin aminonucleo-
side nephrotoxicity. Am J Physiol Renal Physiol 2009;296:F1307-F1313.
 8.  Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, et al. Rifampin en-
hances the glucose-lowering effect of metformin and increases OCT1 
mRNA levels in healthy participants. Clin Pharmacol Ther 2011;89:416-
421.
 9.  Lickteig AJ, Cheng X, Augustine LM, Klaassen CD, Cherrington NJ. Tissue 
distribution, ontogeny and induction of the transporters Multidrug and toxin 
extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci 
2008;83:59-64.
10.  Maeda T, Oyabu M, Yotsumoto T, Higashi R, Nagata K, Yamazoe Y, et al. 
Effect of pregnane X receptor ligand on pharmacokinetics of substrates of 
organic cation transporter Oct1 in rats. Drug Metab Dispos 2007;35:1580-
1586.
11.  Kim W, Seong J, An JH, Oh HJ. Enhancement of tumor radioresponse by 
wortmannin in C3H/HeJ hepatocarcinoma. J Radiat Res 2007;48:187-
195.
12.  Seong J, Oh HJ, Kim J, An JH, Kim W. Identification of proteins that regu-
late radiation-induced apoptosis in murine tumors with wild type p53. J 
Radiat Res 2007;48:435-441.
13.  Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression 
of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is 
affected by genetic factors and cholestasis in human liver. Hepatology 
2009;50:1227-1240.
14.  Nie W, Sweetser S, Rinella M, Green RM. Transcriptional regulation of 
murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-alpha 
and -gamma. Am J Physiol Gastrointest Liver Physiol 2005;288:G207-
G212.
15.  Xu S, Sun AQ, Suchy FJ. A novel RARα/CAR-mediated mechanism for 
regulation of human organic solute transporter-β gene expression. Am J 
Physiol Gastrointest Liver Physiol 2014;306:G154-162.
Sung Kweon Cho et al.
